Aldo D’IMperio

Aldo D’IMperio

Auto-generated profile, based on publicly available information

Aldo D’IMperio

University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
SDStefano Damiani
Stefano Damiani
RSRiccardo Stefanelli
Riccardo Stefanelli
LFLydia Fortea
Lydia Fortea
ADAldo D’IMperio
Aldo D’IMperio
MCMatteo Calò
Matteo Calò
PFPaolo Fusar-Poli
Paolo Fusar-Poli
Negative symptoms (avolition, anhedonia, asociality, blunted affect, and alogia) are among the most disabling features of schizophrenia spectrum disorders. In the absence of treatment consensus guidelines, this PRISMA-compliant meta-analysis (PROSPERO: CRD42024613967) evaluated efficacy and clinical significance of interventions targeting this dimension. Web of Science/PsycInfo databases were searched from inception to December 2024. Five categories (antipsychotics, other pharmacological agents, brain stimulation, psychosocial, and lifestyle interventions) were analyzed across short/middle/long follow-up times. Categories were divided into 27 subcategories (e.g., ‘other pharmacological agents’ divided in 14 subcategories including antidepressants, antibiotics, immunomodulators) regardless of follow-up, assessing evidence with GRADE criteria. The primary outcome was the change in negative symptom severity, measured with validated scales (PANSS/SANS/BPRS/CAINS/BNSS) as standardized mean differences (SMD). A clinically meaningful SMD threshold was estimated from the regression between SMD and one-point reductions on the Clinical Global Impression-Severity (CGI-S) scale. This study meta-analyzed 451 trials (n = 42566). The clinically meaningful threshold, obtained from 122 trials reporting CGI-S, was SMD ≥ 0.457. In 214 high-quality studies (n = 19746), 2 category-by-follow-up combinations and 16 subcategories showed significant improvements. Clinically meaningful SMDs for subcategories were antibiotics (0.95; CI: 0.18–1.71; moderate-GRADE), integrated psychosocial interventions (0.93; CI: 0.53–1.33; very-low-GRADE), antidepressants (0.76; CI: 0.33–1.19; moderate-GRADE), physical activity (0.68; CI: 0.39–0.96; very-low-GRADE), transcranial current stimulation (0.52; CI: 0.17–0.86; low-GRADE), and immunomodulators (0.47; CI: 0.26–0.67; high-GRADE), typically as adjuncts to antipsychotics. Heterogeneity was the main limitation. While selected interventions may yield meaningful improvements, more rigorous designs are needed to identify reliable, personalized and scalable treatment options.